A 62-year-old man with moderate COPD is being counselled on his inhaler therapy. Regarding the properties and clinical use of anticholinergic bronchodilators, all of the following are true EXCEPT:

Explanation

## Anticholinergic Bronchodilators in COPD Management ### Mechanism and Classification **Key Point:** Anticholinergics block muscarinic M3 receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction. They are particularly valuable in COPD where parasympathetic tone is elevated. ### Pharmacological Properties | Property | Short-Acting (Ipratropium) | Long-Acting (Tiotropium, Aclidinium) | |----------|---------------------------|--------------------------------------| | **Onset** | 15–30 minutes | 15–30 minutes (same) | | **Peak effect** | 1–2 hours | 1–2 hours (same) | | **Duration** | 4–6 hours | 12–24 hours | | **Systemic absorption** | Minimal (quaternary amine) | Minimal (quaternary amine) | | **Dosing** | 3–4 times daily | Once or twice daily | ### Correct Statements **Statement 1 (Ipratropium properties):** ✓ **CORRECT** - Ipratropium is a quaternary ammonium compound (hydrophilic, charged) - Poor GI and pulmonary absorption → minimal systemic side effects - Local bronchodilation without anticholinergic toxicity (dry mouth, urinary retention, tachycardia) **Statement 2 (M3 receptor blockade):** ✓ **CORRECT** - M3 muscarinic receptors mediate smooth muscle contraction and mucus secretion - Anticholinergics block these receptors, preventing bronchoconstriction - This is the primary mechanism of action **Statement 3 (Onset of action):** ✗ **INCORRECT** - **Long-acting anticholinergics (LAMAs) have the SAME onset as short-acting anticholinergics (SAMAs)** - Both require 15–30 minutes for onset - The difference is in **duration**, not onset: LAMAs last 12–24 hours; SAMAs last 4–6 hours - This is a high-yield distinction frequently tested **Statement 4 (COPD efficacy):** ✓ **CORRECT** - Anticholinergics reduce mucus hypersecretion (common in COPD) - They improve mucociliary clearance by reducing secretion volume - They are first-line agents in COPD, especially when beta-2 agonists are inadequate ### High-Yield Distinction **High-Yield:** Do NOT confuse onset with duration: - **Onset** = time to first effect (15–30 min for all anticholinergics) - **Duration** = how long the effect lasts (4–6 hours for SAMAs; 12–24 hours for LAMAs) **Clinical Pearl:** In COPD, LAMAs (tiotropium, umeclidinium, aclidinium) are preferred over SAMAs because once-daily dosing improves adherence and provides sustained bronchodilation throughout the day. **Mnemonic:** **LAMA vs SAMA** — **L**ong-acting = **L**asts longer; **S**hort-acting = **S**horter duration. Onset is the same for both.